|
1
|
George JN and Amaresh A: Neonatal
mortality and morbidity in pregnancy induced hypertension: A
prospective observational study. J Evol Med Dent Sci. 3:5238–5246.
2014.
|
|
2
|
Zhuang C, Gao J, Liu J, Wang X, He J, Sun
J, Liu X and Liao S: Risk factors and potential protective factors
of pregnancy-induced hypertension in China: A cross-sectional
study. J Clin Hypertens (Greenwich). 21:618–623. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kintiraki E, Papakatsika S, Kotronis G,
Goulis DG and Kotsis V: Pregnancy-induced hypertension. Hormones
(Athens). 14:211–223. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Andrews L and Patel N: Correlation of
serum lactate dehydrogenase and pregnancy induced hypertension with
its adverse outcomes. Int J Res Med Sci. 4:1347–1350. 2016.
|
|
5
|
Easterling TR: Pharmacological management
of hypertension in pregnancy. Semin Perinatol. 38:487–495.
2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen C and Tao R: The impact of magnesium
sulfate on pain control after laparoscopic cholecystectomy: A
meta-analysis of randomized controlled studies. Surg Laparosc
Endosc Percutan Tech. 28:349–353. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lamarca B, Brewer J and Wallace K:
IL-6-induced pathophysiology during pre-eclampsia: Potential
therapeutic role for magnesium sulfate? Int J Interferon Cytokine
Mediat Res. 2011:59–64. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Alexander JM, McIntire DD, Leveno KJ and
Cunningham FG: Selective magnesium sulfate prophylaxis for the
prevention of eclampsia in women with gestational hypertension.
Obstet Gynecol. 108:826–832. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sharma KJ, Greene N and Kilpatrick SJ:
Oral labetalol compared to oral nifedipine for postpartum
hypertension: A randomized controlled trial. Hypertens Pregnancy.
36:44–47. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Webster LM, Myers JE, Nelson-Piercy C,
Harding K, Cruickshank JK, Watt-Coote I, Khalil A, Wiesender C,
Seed PT and Chappell LC: Labetalol versus nifedipine as
antihypertensive treatment for chronic hypertension in pregnancy: A
randomized controlled trial. Hypertension. 70:915–922.
2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Martínez-Jiménez C, Cruz-Angeles J, Videa
M and Martínez LM: Co-amorphous simvastatin-nifedipine with
enhanced solubility for possible use in combination therapy of
hypertension and hypercholesterolemia. Molecules.
23(2161)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wen J and Li X: Effect of magnesium
sulfate combined with phentolamine and nifedipine for gestational
hypertension and serum levels of LIF and apelin. J Coll Physicians
Surg Pak. 29:231–234. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun Q, Xin F, Wen X, Lu C, Chen R and Ruan
G: Protective effects of different kinds of filtered water on
hypertensive mouse by suppressing oxidative stress and
inflammation. Oxid Med Cell Longev. 2018(2917387)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Niwa Y, Kanda H, Shikauchi Y, Saiura A,
Matsubara K, Kitagawa T, Yamamoto J, Kubo T and Yoshikawa H:
Methylation silencing of SOCS-3 promotes cell growth and migration
by enhancing JAK/STAT and FAK signalings in human hepatocellular
carcinoma. Oncogene. 24:6406–6417. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang Y, Lewis DF, Gu Y, Zhao S and Groome
LJ: Elevated maternal soluble Gp130 and IL-6 levels and reduced
Gp130 and SOCS-3 expressions in women complicated with
preeclampsia. Hypertension. 57:336–342. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yang GX, Sun Y, Tsuneyama K, Zhang W,
Leung PS, He XS, Ansari AA, Bowlus C, Ridgway WM and Gershwin ME:
Endogenous interleukin-22 protects against inflammatory bowel
disease but not autoimmune cholangitis in dominant negative form of
transforming growth factor beta receptor type II mice. Clin Exp
Immunol. 185:154–164. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cubro H, Kashyap S, Nath MC, Ackerman AW
and Garovic VD: The role of interleukin-10 in the pathophysiology
of preeclampsia. Curr Hypertens Rep. 20(36)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Krishnan SM, Sobey CG, Latz E, Mansell A
and Drummond GR: IL-1β and IL-18: Inflammatory markers or mediators
of hypertension? Br J Pharmacol. 171:5589–5602. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liu LS: Writing Group of 2010 Chinese
Guidelines for the Management of Hypertension. 2010 Chinese
guidelines for the management of hypertension. Zhonghua Xin Xue
Guan Bing Za Zhi. 39:579–615. 2011.PubMed/NCBI(In Chinese).
|
|
20
|
Świątkowska-Stodulska R, Kmieć P,
Stefańska K and Sworczak K: Renin-Angiotensin-aldosterone system in
the pathogenesis of pregnancy-induced hypertension. Exp Clin
Endocrinol Diabetes. 126:362–366. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cai G, Zhang B, Weng W, Yang L, Shi G, Xue
S and Fu X: Associations of pregnancy-associated plasma protein-A
level with essential hypertension and hypertensive disorders in
pregnancy in Chinese population: A meta-analysis of 20 research
studies involving 3332 individuals. BMJ Open.
5(e008210)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Xu Q, Fan D, Li F and Zhang Z: Influence
of serum HMW adiponectin level in patients with pregnancy-induced
hypertension syndrome on the occurrence of eclampsia in secondary
pregnancy. Exp Ther Med. 14:4972–4976. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhou Y, Chen ZH, Zhao XL, Qiao YH and Guo
RX: Effect of serum high molecular weight adiponectin level on the
occurrence of eclampsia during subsequent pregnancy in patients
with primary pregnancy induced hypertension. Eur Rev Med Pharmacol
Sci. 21:213–218. 2017.PubMed/NCBI
|
|
24
|
Alves S, Churlaud G, Audrain M,
Michaelsen-Preusse K, Fol R, Souchet B, Braudeau J, Korte M,
Klatzmann D and Cartier N: Interleukin-2 improves amyloid
pathology, synaptic failure and memory in Alzheimer's disease mice.
Brain. 140:826–842. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Parulekar AD, Kao CC, Diamant Z and
Hanania NA: Targeting the interleukin-4 and interleukin-13 pathways
in severe asthma: Current knowledge and future needs. Curr Opin
Pulm Med. 24:50–55. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dinarello CA: Interleukin-1 mediated
autoinflammation from heart disease to cancer. In: Textbook of
Autoinflammation. Hashkes PJ, Laxer RM and Simon A (eds). Springer,
Cham, pp711-725, 2019.
|
|
27
|
Ridker PM, Libby P, MacFadyen JG, Thuren
T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM and
Glynn RJ: Modulation of the interleukin-6 signalling pathway and
incidence rates of atherosclerotic events and all-cause mortality:
Analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes
Study (CANTOS). Eur Heart J. 39:3499–3507. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vijayan AL, Vanimaya Ravindran S, Saikant
R, Lakshmi S, Kartik R and Manoj G: Procalcitonin: A promising
diagnostic marker for sepsis and antibiotic therapy. J Intensive
Care. 5(51)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Magee LA, Miremadi S, Li J, Cheng C, Ensom
MH, Carleton B, Côté AM and von Dadelszen P: Therapy with both
magnesium sulfate and nifedipine does not increase the risk of
serious magnesium-related maternal side effects in women with
preeclampsia. Am J Obstet Gynecol. 193:153–163. 2005.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chen Q, Zhao M, Guo F, Yin YX, Xiao JP,
Stone PR and Chamley LW: The reduction of circulating levels of
IL-6 in pregnant women with preeclampsia by magnesium sulphate and
nifedipine: In vitro evidence for potential mechanisms. Placenta.
36:661–666. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhao S, Gu Y, Dong Q, Fan R and Wang Y:
Altered interleukin-6 receptor, IL-6R and gp130, production and
expression and decreased SOCS-3 expression in placentas from women
with pre-eclampsia. Placenta. 29:1024–1028. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wei T, Orfanidis K, Xu N, Janson P, Ståhle
M, Pivarcsi A and Sonkoly E: The expression of microRNA-203 during
human skin morphogenesis. Exp Dermatol. 19:854–856. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang Y, Dong Q, Gu Y and Groome LJ:
Up-regulation of miR-203 expression induces endothelial
inflammatory response: Potential role in preeclampsia. Am J Reprod
Immunol. 76:482–490. 2016.PubMed/NCBI View Article : Google Scholar
|
